Takeda Pharmaceutical Li...

NYSE: TAK · Real-Time Price · USD
14.97
0.17 (1.15%)
At close: Aug 15, 2025, 9:58 AM

Takeda Pharmaceutical Income Statement

Financials in JPY. Fiscal year is April - March.
Fiscal Year Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Revenue
4,581.6B 4,579B 4,546.1B 4,413.1B 4,263.8B 4,169B 4,154.4B 4,113.6B 4,027.5B 3,944.6B 3,749.4B 3,591.9B 3,569B 3,466B 3,401.4B 3,345.6B
Cost of Revenue
1,885.5B 2,072.6B 2,035.2B 1,842.1B 1,613.4B 1,353.9B 1,310.4B 1,272.3B 1,244.1B 1,242.7B 1,188.1B 1,158.5B 1,106.8B 1,051.9B 1,023.6B 997.49B
Gross Profit
2,696.1B 2,506.4B 2,510.8B 2,571B 2,650.3B 2,815.1B 2,844B 2,841.3B 2,783.4B 2,701.9B 2,561.2B 2,433.4B 2,462.2B 2,414.1B 2,377.8B 2,348.1B
Operating Income
396B 471.44B 509.41B 275.82B 224.68B 312.71B 354.78B 508.56B 490.5B 400.32B 369.82B 362.81B 460.84B 613B 639.66B 590.54B
Interest Income
34.79B 40.78B 62.57B 67.82B 63.59B 65.39B 85.28B 90.7B 125.17B 117.39B 79.85B 71.93B 56.86B 104.35B 128.61B 131.76B
Pretax Income
175.79B 231.83B 266.68B 51.33B 49.05B 148.23B 194.12B 354.65B 375.09B 273.13B 238.17B 235.07B 302.57B 487.5B 525.1B 458.92B
Net Income
107.88B 208.06B 290B 149.92B 144.07B 178.22B 191.63B 301.4B 317.02B 274.52B 213.17B 197.39B 230.06B 438.52B 473.11B 431.18B
Selling & General & Admin
1,104.8B 1,094.1B 1,091.1B 1,075.7B 1,053.8B 1,023.4B 1,018.2B 1,013.9B 997.31B 965.94B 934.72B 898B 886.36B 897.32B 888.89B 893.13B
Research & Development
730.22B 710.08B 727.26B 735.65B 729.92B 695.01B 682.26B 652.46B 633.33B 616.01B 569.76B 547.21B 526.09B 495.75B 484.94B 471.49B
Other Expenses
453.83B 219.53B -1.21B -1.21B -1.21B -1.21B -1.01B -1.01B 152.97B 352.44B 497.4B 625.38B 588.87B 578.97B 535.28B 563.87B
Operating Expenses
2,288.8B 2,023.7B 2,028.7B 2,333.7B 2,464.2B 2,540.9B 2,489.2B 2,332.8B 2,292.9B 2,301.6B 2,191.4B 2,070.6B 2,001.3B 1,801.1B 1,738.1B 1,757.5B
Interest Expense
128.15B 175.33B 241.9B 219.97B 219.85B 215.6B 228.78B 236.06B 231.95B 189.02B 155.98B 141.85B 157.45B 232.69B 248.66B 272.85B
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
4,174.3B 4,096.4B 4,064B 4,175.8B 4,077.6B 3,894.8B 3,799.6B 3,605.1B 3,537B 3,544.3B 3,379.5B 3,229.1B 3,108.2B 2,853B 2,761.8B 2,755B
Income Tax Expense
66.94B 26.61B -20.45B -95.73B -91.41B -30.1B 2.4B 53.23B 58.05B -1.4B 24.97B 37.6B 72.41B 48.81B 51.8B 27.54B
Shares Outstanding (Basic)
3.16B 3.17B 3.17B 3.14B 3.14B 3.14B 3.13B 3.11B 3.11B 3.11B 3.1B 3.09B 3.11B 3.13B 3.14B 3.09B
Shares Outstanding (Diluted)
3.16B 3.17B 3.22B 3.18B 3.14B 3.17B 3.13B 3.13B 3.23B 3.14B 3.13B 3.11B 3.15B 3.15B 3.16B 3.11B
EPS (Basic)
34.31 65.97 92.16 47.75 46.15 57.12 61.75 96.97 102.19 88.52 68.66 63.39 73.96 140.65 151.74 138.41
EPS (Diluted)
33.44 65.10 90.95 47.02 45.61 56.22 60.80 95.88 101.10 87.85 68.26 63.06 73.57 140.21 151.17 137.92
EBITDA
1,139.1B 1,145.1B 1,244.1B 1,064.1B 1,027.4B 1,097.9B 1,129.8B 1,201.8B 1,176.9B 1,050.6B 990.48B 956.28B 1,024.8B 1,230.8B 1,279.3B 1,239.3B
EBIT
381.67B 289.52B 411.3B 185.51B 183.83B 322.6B 381.68B 537.99B 554.32B 495.33B 427.33B 410.1B 493.2B 602.36B 626.61B 573.78B
Depreciation & Amortization
761.4B 758.37B 758.48B 806.27B 785.55B 760.21B 750.03B 677.62B 664.4B 655.26B 625.67B 598.49B 583.15B 570.27B 562.74B 561.03B